Signal: Novo Nordisk market cap higher than Danish GDP due to obesity drugs

Novo Nordisk, manufacturer of GLP-1 antagonist drugs Wegovy and Ozempic, now has a higher market capitalisation than the yearly GDP of its home country, Denmark.

At the time of writing the International Monetary Fund projects Denmark’s 2023 GDP to reach $405.6bn, whilst Novo’s market cap sits around $418.1bn.